James C. Gale - Mr. Gale joined Sanders Morris Harris in September 1998 to serve as managing partner of LOF Partners LLC which manages the three life sciences private equity funds. During the previous seven years, Mr. Gale was head of investment banking for Gruntal & Co., LLC, a large brokerage and investment banking company. At Gruntal, he established corporate finance groups specializing in health care, media/communications and technology. In addition, Mr. Gale consummated a number of private investments as principal. These include Andrx Corporation, Royce Laboratories, Lifecell Corporation, Neurocrine Biosciences and BML Pharmaceuticals. Prior to joining Gruntal, he originated and managed private equity investments for the Home Insurance Co., Gruntal’s parent. Earlier in his career, Mr. Gale was a senior investment banker at E.F. Hutton & Co. and Adam Cohen Securities, Inc. an investment banking firm specializing in the savings and loan industry. Mr. Gale received his M.B.A. from The University of Chicago and serves on the board of directors of Latshaw Enterprises Inc., Relm Wireless Corporation, and several private company boards including Avantium Technologies BV, Cydex Inc. and Valera Pharmaceuticals Inc (as Chairman).

  

Jerald S. Cobbs - Mr. Cobbs has more than twenty years’ experience as an investment banker and as a principal in the health sciences and biotech industries. During this period he has worked an executive officer of an early-stage biotech company focused on treatment of several genetic diseases, which is minority owned by SMH and its affiliates. Mr. Cobbs joined Harris Web & Garrison Inc. (which merged with SMH in 2000) in 1994 as head of health care investment banking. From 1992 to 1994, Mr. Cobbs served as the assistant director of technology development at the University of Texas – M.D. Anderson Cancer Center, in the Houston Medical Center. During his tenure at M.D. Anderson, he helped form two gene therapy companies: Introgen Therapeutics (Nasdaq: INGN), a pioneer in gene-based therapies for a variety of cancers based in Austin, Texas and Rgene Therapeutics, which was sold to Targeted Genetics, Inc. (Nasdaq: TGEN). From 1998 to April of 2000, Mr. Cobbs was chairman and chief executive officer of Quantitive Diagnostic Laboratories, a cancer diagnostic and image analysis company based in Chicago. Prior to that time, Mr. Cobbs spent twelve years as an investment research analyst, last serving as senior investment analyst with Rauscher Pierce Refnes, Inc. in 1990. Mr. Cobbs received his M.B.A. from the University of Houston, Clear Lake.

Kenneth Ch’uan-k’ai Leung - Mr. Leung runs The Environmental Opportunities Fund I and II, which represents $113 million of private equity partnership monies, and is an advisor to several environmental companies. Prior to joining Sanders Morris Harris in 1995, Mr. Leung was a Managing Director at Smith Barney from 1978 to 1994. He has been an Institutional Investor "All Star" analyst for twenty-one years and has been involved in many of the major environmental service investment banking transactions over the past thirty- three years. Mr. Leung was a Vice President at F. Eberstadt & Co. from 1974 to 1978 and an Assistant Treasurer at Chemical Bank from 1968 to 1974. Mr. Leung is a director of several Fund portfolio companies.

Bruce R. McMaken - Mr. McMaken is an officer in the Investment Banking Group. Mr. McMaken also serves on the Investment Committees of the Environmental Opportunities Fund, a $38 million private equity fund, and Environmental Opportunities Fund II, a $75 million private equity fund, both of which are managed by affiliates of SMH. Prior to joining the firm in 1992, Mr. McMaken was involved in providing independent corporate finance and venture capital advisory services to clients primarily in the environmental services, biotechnology and real estate development industries. He received a Bachelor of Arts degree from Cornell University. He serves as director for Knight Trading Group (NITE), which operates the largest Nasdaq and third-market equity market makers in the United States, IESI Corporation, a solid waste collection and disposal company, and Northstar Passenger Services, a transportation services company operating in Canada.

Al Hansen – Mr. Hansen is a Managing Director with Sanders Morris Harris and has assisted Mr. Gale in managing the firm’s life sciences investment activities since 2001. Mr. Hansen has over 20 years experience as a private equity investor and as an investment banker. He is currently Chairman and was interim CEO of Questcor Pharmaceuticals (AMEX:QSC), a portfolio company. From 2000 - 2001, Mr. Hansen was a private consultant and advisor to several startup and smaller venture-backed private companies. From 1993 – 1999, Mr. Hansen was a principal of Darby Overseas Investments, Ltd., a private equity firm with a focus on emerging markets. In 1992, Mr. Hansen was Director of Corporate Finance at the U.S. Treasury. From 1986 – 1991, he was an investment banker with Dillon Read & Co. Inc., focusing on mergers and acquisitions. From 1983 – 1985, he was an investment banker at E.F. Hutton & Co. Mr. Hansen also served in the U.S. Army as an Infantry and Special Forces officer. Mr. Hansen has an A.B. from Princeton University and an M.B.A. from the Wharton School, University of Pennsylvania. He is currently a director of BioPro Pharmaceuticals, Cedarburg Pharmaceuticals, LearnWright, Malladi Drugs and Pharmaceuticals, and Molecular Medicine BioServices (where he also serves as Chairman).